Akoya Biosciences Inc (AKYA)
4.04
+0.05
(+1.25%)
USD |
NASDAQ |
May 03, 16:00
4.04
0.00 (0.00%)
Pre-Market: 20:00
Akoya Biosciences Accounts Receivable (Quarterly): 16.99M for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 16.99M |
September 30, 2023 | 16.10M |
June 30, 2023 | 12.87M |
March 31, 2023 | 12.94M |
December 31, 2022 | 9.729M |
September 30, 2022 | 8.68M |
June 30, 2022 | 10.47M |
Date | Value |
---|---|
March 31, 2022 | 11.31M |
December 31, 2021 | 9.444M |
September 30, 2021 | 9.605M |
June 30, 2021 | 8.158M |
March 31, 2021 | 6.59M |
December 31, 2020 | 6.47M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
6.47M
Minimum
Dec 2020
16.99M
Maximum
Dec 2023
10.72M
Average
9.729M
Median
Dec 2022
Accounts Receivable (Quarterly) Benchmarks
Bruker Corp | 475.40M |
Azenta Inc | 155.93M |
Harvard Bioscience Inc | 16.10M |
Bionano Genomics Inc | 9.319M |
Singular Genomics Systems Inc | 0.565M |